A new biotech out of Dana-Farber wants to join the long non-coding RNA party, with help from Bob Langer
Biotechs focusing on long non-coding RNAs have proliferated in recent years, and another new company announced its launch early Tuesday.
NextRNA Therapeutics came out of stealth with $56 million in financing — $9.3 million from a seed financing and $46.8 million from a Series A — as it looks to join the increasingly crowded “lncRNA” biotech space. Founded in January 2021, the company comes out of research from the Dana-Farber Cancer Institute, and Kenneth Anderson and Bob Langer have lent their names as co-founders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.